KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Efficacy and safety of adjunctive use of rifaximin in preventing radiotherapy-induced diarrhea in cancer patients: a randomized controlled trial.

Menna A El-Maghraby, Noha O Mansour, Ahmed Ramadan Eldesoky, Moetaza M Soliman

Naunyn Schmiedebergs Arch Pharmacol 10.1007/s00210-026-06083-1

PMID43052387
PMCID-
DOI10.1007/s00210-026-06083-1
发表日期2026-11-18
入排依据:未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
摘要

摘要

Radiation-induced diarrhea (RID) is a common, dose-limiting toxicity in patients with pelvic cancer undergoing radiotherapy. No pharmacological agent is currently approved for its prevention. Rifaximin, a non-absorbable antibiotic with anti-inflammatory and microbiota-modulating properties, may offer protective benefits. This prospective, parallel-group, open-label randomized controlled trial enrolled 80 adults with non-metastatic pelvic cancers receiving curative-intent radiotherapy, with or without chemotherapy. Participants were randomized in 1:1 ratio to receive standard care alone or standard care plus rifaximin 550 mg twice daily throughout radiotherapy. Primary outcome was the incidence of grade ≥ 2 diarrhea assessed by Common Terminology Criteria for Adverse Events (CTCAE v5.0). Secondary outcomes included time to diarrhea onset, stool consistency (Bristol scale), dehydration, quality of life assessed using European Organization for Research and Treatment of Cancer questionnaire (EORTC QLQ-C30), and safety. Patients' follow-up lasted 3 months post-radiotherapy. Seventy-eight patients completed the study. Incidence of grade ≥ 2 diarrhea was comparable between groups (23.1% control vs. 17.9% rifaximin; risk difference [95% CI] - 5.1 [ - 23.0, 12.8]). Time to onset and rescue medication use did not differ significantly. Stool consistency and dehydration rates were comparable. Rifaximin significantly improved global health status at end of radiotherapy (mean difference between control and rifaximin groups [95% CI] - 10.5 [ - 18.5, - 2.4]) and at three months (- 7.0 [ - 13.1, - 1.0]), with lower fatigue (14.5 [4.2, 24.9]) and pain scores (12.8 [3.1, 22.5]). Adverse events were mild and comparable between groups. Adjunctive rifaximin did not reduce incidence or severity of RID but was associated with improved quality of life and symptom burden. Rifaximin was well tolerated. Larger, double-blind trials are warranted to confirm these findings and explore optimized dosing and timing of administration. Registration of the study: https://clinicaltrials.gov/study/NCT06783153.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。